Gregory P. Winter (born 14 April 1951) is a British biochemist best known for transforming laboratory antibody science into a practical route for safe, effective medicines. His early work on 'humanising' animal antibodies and later use of phage display to generate fully human antibodies laid the groundwork for a large class of modern biologic drugs. For these achievements he shared the 2018 Nobel Prize in Chemistry; more information on his background is available via biographical sources.
Scientific contributions and methods
Winter introduced two complementary approaches that addressed a key clinical problem: how to create antibodies that bind targets with high specificity while minimizing immune reactions when given to patients. The first approach, often called antibody humanization (demonstrated in the mid-1980s), involves transplanting the antigen-binding loops of a non‑human antibody into a human antibody framework to preserve binding but reduce immunogenicity. The second approach adapts phage display — a technique that displays peptides or proteins on the surface of bacteriophages — to select human antibody fragments with desired properties directly from large libraries.
Phage display and its significance
Phage display was originally developed by George P. Smith and was extended by many researchers; Winter applied it specifically to antibody fragments, enabling the laboratory selection of molecules with high affinity and specificity without relying on animal immunization. This made it possible to produce fully human antibodies suitable for therapeutic use and accelerated the discovery pipeline from target identification to candidate drug molecules. His Nobel Prize was shared with George P. Smith and Frances H. Arnold, reflecting the complementary nature of their innovations.
Applications and impact
The techniques Winter helped develop are central to modern biologic therapeutics. Monoclonal antibodies derived from humanization and phage display are used to treat cancer, autoimmune and inflammatory diseases, and other conditions. They serve both as direct therapeutics and as targeting vehicles for drug conjugates and diagnostic reagents.
- Improved safety and reduced immune reactions compared with earlier animal-derived antibodies.
- Faster, more reliable discovery of candidate molecules in the lab rather than through animal immunization.
- Broad influence on the biotechnology industry and the development of multiple approved antibody drugs.
Beyond laboratory methods, Winter has been influential in translating research into clinical products and in mentoring scientists in protein engineering and therapeutic development. He has received numerous honors and holds several professional distinctions recognizing his role in bridging fundamental molecular biology and therapeutic innovation.